PROFAST Intervention in Precursor Multiple Myeloma

Trial Title: PROFAST Intervention in Precursor Multiple Myeloma

NCT ID: NCT05565638

Condition: Cancer Prevention
Weight Loss
Smoldering Waldenstrom Macroglobulinemia(WM)
MGUS
Fasting
Multiple Myeloma

Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Waldenstrom Macroglobulinemia
Weight Loss

Conditions: Keywords:
Cancer prevention
Weight loss
Smoldering Waldenstrom Macroglobulinemia(WM)
MGUS
Smoldering Multiple Myeloma
Prolonged nightly fasting
Multiple Myeloma

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Prevention

Masking: None (Open Label)

Intervention:

Intervention type: Behavioral
Intervention name: Prolonged Fasting Intervention
Description: promote a 14-hour fast during the nighttime hours
Arm group label: PROLONGED FASTING INTERVENTION

Intervention type: Behavioral
Intervention name: EDUCATION CONTROL
Description: introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
Arm group label: EDUCATION CONTROL

Summary: This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer. Participants will be randomized into the following two groups: - Group A: PROFAST intervention for 4 months - Group B: Healthy Lifestyle Control group for 4 months

Detailed description: The purpose of this research study is to learn if fasting for a prolonged period of time could be used in the future to help improve body composition and prevent blood cancer in overweight and obese individuals with MGUS, SMM, and SWM. Multiple myeloma is a cancer of the plasma cells, which is an important part of the immune system. Participants with active multiple myeloma generally require treatment. There are currently no approved therapies or prevention strategies for smoldering multiple myeloma or monoclonal gammopathy of undetermined significance. The National Cancer Institute of the National Institutes of Health is supporting this research study by providing funding. This research study is a 4-month randomized trial of prolonged nightly fasting (PROFAST). It is expected that about 40 people will take part in this research study. The total study duration is 4 months. Participants in the study will be randomized, in equal numbers to either the nightly fasting intervention group or a control group. - The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times via the text messaging system. The text messaging system will be used throughout the duration of the study. - For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - BMI >= 25 kg/m2 - Documented diagnosis of MGUS or Smoldering MM(SMM) or Smoldering Waldenstrom Macroglobulinemia(WM) via EMR review. *note: please review case with PI or treating MD if diagnosis is uncertain. - At least 18 years of age - Currently fasting for <14 hours per night, as assessed using 24-hour food recalls - Owns a cell phone and is comfortable sending and receiving text messages - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Diagnosis of overt MM or WM - Patients diagnosed with another malignancy requiring active therapy - Clinical diagnosis of diabetes, which may increase the risk of hypoglycemia with a prolonged fast. Note: patients with diabetes may enroll with consent from MD that manages their clinical care. - Any other condition that, in the investigator's judgment, would contraindicate prolonged nightly fasting or otherwise interfere with participation in the trial, including night shift work, night eating syndrome, taking weight loss medication, or participation in another weight loss program

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Dana Farber Cancer Institute

Address:
City: Boston
Zip: 02115
Country: United States

Status: Recruiting

Contact:
Last name: Catherine Marinac, PhD

Phone: 617-632-4703
Email: CatherineR_Marinac@dfci.harvard.edu

Contact backup:
Last name: Catherine Marinac, PhD

Start date: March 6, 2023

Completion date: May 31, 2025

Lead sponsor:
Agency: Dana-Farber Cancer Institute
Agency class: Other

Collaborator:
Agency: National Cancer Institute (NCI)
Agency class: NIH

Source: Dana-Farber Cancer Institute

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05565638